Latest news with #Glaucoma
Business Wire
3 days ago
- Business
- Business Wire
Glaukos Announces Participation in Wells Fargo Healthcare Conference
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 10:15 a.m. ET in Boston, MA. A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at About Glaukos Glaukos ( is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose ® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.
Yahoo
31-07-2025
- Business
- Yahoo
Glaucoma Global Clinical Trials Market Landscape Report 2025 Featuring Alcon, AbbVie, Santen Pharmaceutical, Pfizer, Kowa, Viatris, Merck, Novartis, Senju Pharmaceutical, Bausch Health
Discover insights with the "Glaucoma - Global Clinical Trials Review, 2025." This comprehensive report outlines the global scenario of glaucoma clinical trials, offering top-line data by region, country, phase, and sponsor type. Leverage key findings to enhance decision-making and optimize strategies in the competitive clinical trials landscape. Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The "Glaucoma - Global Clinical Trials Review, 2025" has been added to offering. The clinical trial report offers a comprehensive overview of the global landscape for Glaucoma clinical trials. This detailed analysis provides key insights into trial numbers and average enrollment rates across leading nations. The report encompasses a thorough coverage of clinical trials by region, country (G7 & E7), phase, trial status, endpoint status, and sponsor type. Additionally, it highlights prominent drugs currently undergoing trials, based on the number of ongoing studies. The analyst Clinical Trial Reports are meticulously compiled using the proprietary Pharma - Clinical Trials Database. Data is aggregated from over 80 clinical trial registries, conferences, journals, and news sources worldwide, and the database is updated dynamically to reflect the latest information. The report significantly enhances decision-making capabilities, empowering stakeholders to craft effective counterstrategies and secure a competitive edge. It should be noted that certain sections of the report may undergo modifications based on data availability and relevance. Scope Provides a snapshot of the global clinical trials landscape. Includes top-level data related to clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status. Reviews key companies involved and lists all trials (title, phase, and status) associated with each company. Details unaccomplished trials (terminated, suspended, or withdrawn) with reasons for non-completion. Discusses enrollment trends from the past five years. Offers the latest industry news from the past three months. Reasons to Buy Facilitates the development of strategic business initiatives related to investment. Identifies optimal locations for conducting clinical trials, maximizing efficiency and cost-effectiveness. Provides top-level analysis of the Global Clinical Trials Market, aiding in the discovery of key business opportunities. Enhances understanding of trial counts and enrollment trends by country in the global therapeutics market. Enables interpretation of clinical trial success rates by presenting comparative scenarios of completed and uncompleted trials. Supports clinical trial assessment for indications at global, regional, and country levels. Key Topics Covered: Report Guidance The analyst Clinical Trials Report Coverage Clinical Trials by Region Clinical Trials by G7 Countries Proportion of Glaucoma to Ophthalmology Clinical Trials Clinical Trials by Phase Clinical Trials by Trial Status Clinical Trials by E7 Countries Proportion of Glaucoma to Ophthalmology Clinical Trials Clinical Trials by Phase Clinical Trials by Trial Status Clinical Trials by Phase Clinical Trials by Trial Status Clinical Trials by Sponsor Type Prominent Sponsors Prominent Drugs Latest Clinical Trials News on Glaucoma Jun 24, 2025: Perfuse Therapeutics Announces Positive Results from Phase 2 Clinical Trials in Glaucoma and Diabetic Retinopathy Patients May 07, 2025: Galimedix Therapeutics completes SAD portion of Phase I trial of oral GAL-101 May 05, 2025: Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy Apr 24, 2025: Stealth Biotherapeutics To Present New Bevemipretide Data at ARVO Annual Meeting Clinical Trial Profile Snapshots A selection of companies mentioned in this report includes, but is not limited to: Alcon Inc AbbVie Inc Santen Pharmaceutical Co Ltd Pfizer Inc Kowa Co Ltd Viatris Inc Merck & Co Inc Novartis AG Senju Pharmaceutical Co Ltd Bausch Health Companies Inc For more information about this clinical trials report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
